
Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Your AI-Trained Oncology Knowledge Connection!


Dr Schmid discusses considerations for applying recent data updates in HER2-positive breast cancer management to clinical practice.

Peter Schmid, FRCP, MD, PhD, discusses key findings from the phase 1/2 BEGONIA trial in patients with unresectable, metastatic or locally advanced triple-negative breast cancer, highlighting the clinical significance of these findings.

Published: October 25th 2023 | Updated: